Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Kentucky: - King's Daughter's Medical Center — Ashland, Kentucky
- CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
- Baptist Health Corbin — Corbin, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Baptist Health Hardin — Elizabethtown, Kentucky
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Baptist Health Corbin — Corbin, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Baptist Health Hardin — Elizabethtown, Kentucky
- Baptist Health Lexington — Lexington, Kentucky
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Kentucky: - Baptist Health Corbin — Corbin, Kentucky
- Baptist Health Hardin — Elizabethtown, Kentucky
- Baptist Health Lexington — Lexington, Kentucky
- Markey Cancer Center at Lexington Clinic — Lexington, Kentucky
- Baptist Health Hamburg — Lexington, Kentucky
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Kentucky: - Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- Saint Joseph London — London, Kentucky
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Kentucky: - King's Daughter's Medical Center — Ashland, Kentucky
- CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
- CommonSpirit Saint Joseph Medical Center - East Lexington — Lexington, Kentucky
- Owensboro Health Mitchell Memorial Cancer Center — Owensboro, Kentucky
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Kentucky: - UofL Health Brown Cancer Center — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Kentucky: - Saint Elizabeth Medical Center Edgewood — Edgewood, Kentucky
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Kentucky: - Baptist Health Lexington — Lexington, Kentucky
- Baptist Health Hamburg — Lexington, Kentucky
- University of Kentucky - Markey Cancer Center — Lexington, Kentucky
- University of Louisville Hospital — Louisville, Kentucky
- Baptist Health Louisville — Louisville, Kentucky
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 1 Recruiting Industry
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …
Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Kentucky: - UK Markey Cancer Center — Lexington, Kentucky